Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
Ранг среди акций #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Цена акции
$149.90
Последняя синхронизация: 2026-09-18
Рыночная капитализация
$284.92B
Изменение (1 день)
-0.66%
Изменение (1 год)
21.93%
Страна
CH
Торговля Novartis AG (NOVN)

Категория

История дивидендов Novartis AG (NOVN)
Novartis AG (тикер: NOVN) выплатила в общей сложности 29 дивидендов.
Общая сумма всех дивидендов (с учетом дроблений акций): $57.55
Дивидендная доходность (TTM): 0.028
Дивидендные выплаты по Novartis AG (NOVN) с 1997 по 2026
Годовые дивидендные выплаты
Год Дивиденды (с учетом дробления акций) Изменить
2026 (TTM) $3.50 0.00%
2025 $3.50 6.06%
2024 $3.30 3.12%
2023 $3.20 3.23%
2022 $3.10 3.33%
2021 $3.00 1.69%
2020 $2.95 3.51%
2019 $2.85 1.79%
2018 $2.80 1.82%
2017 $2.75 1.85%
2016 $2.70 3.85%
2015 $2.60 6.12%
2014 $2.45 6.52%
2013 $2.30 2.22%
2012 $2.25 2.27%
2011 $2.20 4.76%
2010 $2.10 5.00%
2009 $2.00 25.00%
2008 $1.60 18.52%
2007 $1.35 17.39%
2006 $1.15 9.52%
2005 $1.05 5.00%
2004 $1.00 5.26%
2003 $0.95 5.56%
2002 $0.9 5.88%
2001 $0.85 6.25%
2000 $0.8 10.34%
1999 $0.725 16.00%
1998 $0.625 25.00%
1997 $0.5 0.00%
Список всех дивидендных выплат
Год Дивиденд Изменить
2026 (TTM) $3.50 0.00%
2025 $3.50 6.06%
2024 $3.30 -14.06%
2023 $3.84 23.87%
2022 $3.10 3.33%
2021 $3.00 1.69%
2020 $2.95 3.51%
2019 $2.85 1.79%
2018 $2.80 1.82%
2017 $2.75 1.85%
2016 $2.70 3.85%
2015 $2.60 6.12%
2014 $2.45 6.52%
2013 $2.30 2.22%
2012 $2.25 2.27%
2011 $2.20 4.76%
2010 $2.10 5.00%
2009 $2.00 25.00%
2008 $1.60 18.52%
2007 $1.35 17.39%
2006 $1.15 9.52%
2005 $1.05 5.00%
2004 $1.00 5.26%
2003 $0.95 5.56%
2002 $0.9 -97.35%
2001 $34.00 6.25%
2000 $32.00 10.34%
1999 $29.00 16.00%
1998 $25.00 25.00%
1997 $20.00 0.00%
Дивиденды аналогичных компаний или конкурентов
Компания Количество дивидендных выплат Страна
215.00%
US
225.00%
US
53.00%
US
33.00%
CH
223.00%
US